JOSÉ ÁNGEL
HERNÁNDEZ RIVAS
Profesor asociado de Ciencias de la Salud
Hospital Universitario La Paz
Madrid, EspañaHospital Universitario La Paz-ko ikertzaileekin lankidetzan egindako argitalpenak (24)
2024
2023
-
COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
Cancers, Vol. 15, Núm. 5
-
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655
-
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry
International Journal of Antimicrobial Agents, Vol. 62, Núm. 4
-
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
eClinicalMedicine, Vol. 58
2022
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
-
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Frontiers in Oncology, Vol. 12
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Blood, Vol. 139, Núm. 10, pp. 1588-1592
-
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
American Journal of Hematology
2021
-
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 12, pp. e985-e999
2020
-
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
Experimental Hematology and Oncology
-
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study
Journal of Hematology and Oncology, Vol. 13, Núm. 1
-
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Blood Cancer Journal, Vol. 10, Núm. 10
2017
-
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice
International Journal of Hematology, Vol. 106, Núm. 4, pp. 508-516
-
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Haematologica, Vol. 102, Núm. 1, pp. 103-109
-
Use of eltrombopag for secondary immune thrombocytopenia in clinical practice
British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970
2016
-
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice
European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302
-
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
British Journal of Haematology, Vol. 172, Núm. 5, pp. 786-793